Modera Wealth Management LLC Acquires 3,799 Shares of AbbVie Inc. $ABBV

Modera Wealth Management LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 5.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,484 shares of the company’s stock after purchasing an additional 3,799 shares during the quarter. Modera Wealth Management LLC’s holdings in AbbVie were worth $16,852,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ABBV. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at approximately $28,000. Imprint Wealth LLC grew its position in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares in the last quarter. Westend Capital Management LLC acquired a new stake in AbbVie during the fourth quarter worth approximately $29,000. IFC & Insurance Marketing Inc. bought a new position in AbbVie during the 4th quarter worth $31,000. Finally, Legacy Wealth Managment LLC ID increased its stake in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Citigroup upped their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Finally, Cantor Fitzgerald raised their target price on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $267.67.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

AbbVie Stock Up 0.1%

Shares of ABBV opened at $254.53 on Friday. The stock has a market cap of $449.70 billion, a PE ratio of 125.38, a PEG ratio of 0.84 and a beta of 0.30. AbbVie Inc. has a 12-month low of $184.63 and a 12-month high of $261.64. The business has a 50-day simple moving average of $229.80 and a two-hundred day simple moving average of $221.94.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the previous year, the business posted $2.46 earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, equities research analysts expect that AbbVie Inc. will post 14.16 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.